logo
Training Reduces Clinicians' Obesity Bias, Improves Practice

Training Reduces Clinicians' Obesity Bias, Improves Practice

Medscape4 hours ago

Many healthcare providers (HCPs) harbor bias against people with excess weight or obesity, and that stigmatization can negatively affect patient care. Now, an innovative two-endpoint continuing medical education (CME) initiative has shown that clinicians can change when brought face to face with their negative attitudes and less than optimal referral behaviors regarding patients with obesity.
Amanda Velazquez, MD
Reporting in the Journal of General Internal Medicine, researchers led by Amanda Velazquez, MD, of the Center for Weight Management and Metabolic Health and the Jim and Eleanor Randall Department of Surgery at Cedars-Sinai Medical Center in Los Angeles, found a 4-hour CME program, conducted in April 2021, significantly reduced HCPs' self-reported negative stereotypes compared with baseline. Self-reported empathy and confidence in caring for patients with obesity significantly increased immediately post intervention and endured at 4- and 12-month follow-up.
Additionally, the 4-hour symposium led to objectively improved diagnosis and referral to obesity care for patients treated across different specialties.
'There is considerable gap in the education of healthcare professionals about obesity,' Velazquez told Medscape Medical News , adding that established data have confirmed the existence of anti-weight bias among HCPs. 'Our study was unique in that it had a broad target group and invited professionals across all specialties from plastic surgeons and Ob/Gyns to nurses and emergency medical technicians. Our goal was to move the needle toward greater comfort in referring their patients to appropriate obesity management.'
She noted that excessive weight exacerbates many conditions treated outside of obesity medicine, such as psoriasis, cardiometabolic disease, and impaired fertility.
The Intervention
Conducted at a single site in the Kaiser Permanente Southern California healthcare system, the symposium invited a diverse population of 472 eligible HCPs.
Weight Bias: Weight bias was assessed by a 16-item questionnaire originally developed for medical students by Robert F. K ushner and colleagues, designed to assess negative prejudicial beliefs about patients with obesity. This measure captured three types of weight bias: negative obesity stereotypes (eg, 'Individuals with obesity have themselves to blame'); empathy for patients (eg, 'People with obesity feel stigmatized by the medical profession'); and confidence in clinical interaction with patients with obesity (eg, 'I feel comfortable talking to people about their weight').
As a result of the program, negative obesity stereotypes among attendees, according to the post-program questionnaire, were significantly reduced over baseline levels (2.81 ± 0.47 vs 2.50 ± 0.46; P < .001), while both their empathy (3.33 ± 0.64 vs 3.47 ± 0.63; P = .006) and confidence (3.10 ± 0.86 vs 3.85 ± 0.79; P < .001) significantly increased.
Practice Patterns: Behavioral outcomes of interest, according to electronic medical records, were participants' objective practice changes regarding obesity diagnosis and referrals to healthy lifestyle programs, obesity medicine, and bariatric surgery. Comparative analyses were done for 218 attendees and 89 nonparticipants.
After adjustment for years in practice, race/ethnicity, gender, profession type, practice type, and panel size, HCPs who attended the program had significantly increased odds of obesity diagnosis and obesity-related referrals in the 12 months following the intervention vs those not attending.
Specifically, compared with nonattendees, participants had increased odds of changes across several measures. Diagnosing obesity: odds ratio [OR], 1.60; (95% CI,1.54-1.66); referring patients to healthy lifestyle programs: OR, 1.27 (95% CI, 1.19-1.36); and referrals to an obesity medicine specialty clinic: OR, 1.87 (95% CI, 1.63-2.14). For patients with a BMI ≥ 35, the post-intervention OR for referral to bariatric surgery was 2.12 (95% CI, 1.70-2.67) in the 12 months following the intervention. The comparison group's odds either decreased or did not change.
As to participation by profession type, physicians were the most likely to attend, with physicians from family medicine, internal medicine, and obstetrics/gynecology more likely to participate than those from orthopedics and ophthalmology.
While Velazquez was not surprised by the level of anti-weight bias the symposium revealed, she was not prepared for the magnitude of objective change it effected in practice patterns. 'The increase in the number of referrals to obesity care was so overwhelming, we had to change the BMI eligibility criterion to handle the influx,' she said. With referrals to the obesity clinic doubling, the threshold for new referrals was raised from BMI ≥ 30 to BMI ≥ 35 to address the overwhelming demand.
Leslie Heinberg, PhD
Offering a nonparticipant's perspective on the intervention, Leslie Heinberg, PhD, a professor of medicine and vice chair for psychology in the Department of Psychiatry and Psychology at the Cleveland Clinic in Cleveland, called it 'an interesting and comprehensive study that goes beyond previous work in attitudinal change to look at change in actual practice behavior around obesity.'
She was not surprised at the shift in attitude immediately after the symposium. 'We all know the right answers to give, but the change in attitudes persisted long after the intervention,' In her practice, patients often report experiencing weight stigma during interaction with their HCPs. 'But healthcare should be sensitive to patients across the entire weight spectrum.'
Heinberg noted HCPs typically get little or no training in obesity issues, including the psychological aspects of this complex multifactorial condition. 'They might get one lecture during training, but 40% of the patients they treat will have obesity,' she said. Training is needed in how to talk to patients about excess weight. Her institution requires all new hires in any clinical capacity to have on-boarding training in obesity bias, with a yearly refresher course as well.
Carolynn Francavilla, MD, an obesity medicine specialist and owner of Green Mountain Partners for Health in Lakewood, Colorado, also applauded the study. 'As someone who dedicates a significant amount of my time to developing CME and educating clinicians, I find it very encouraging that this study was able to demonstrate both reduced weight bias and improved referrals for care,' she told Medscape Medical News. 'While most physicians are now aware of treatment options, many do not understand the chronic nature of the disease and many still believe that willpower is enough to treat obesity.'
The authors concluded that a focused CME intervention aimed at mitigating HCPs' weight bias and behavior can lead to improved diagnosis and referral to the full range of current options in obesity care. 'We're hoping to apply the intervention in other groups to see if it has the same positive impact on practice,' Velazquez said. 'But it will need some updating since the original interventions was conducted in 2021 before the explosion of GLP-1 therapy.'
Future research should focus on integrating obesity pharmacotherapy into the CME content and further examining practice behaviors. 'In addition to a randomized trial of the intervention, future research should also assess longitudinal practice changes beyond 1 year, the authors wrote.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Latticework Capital Management Announces Partnership with First Medical Associates, a Leading Primary Care Provider in Maryland
Latticework Capital Management Announces Partnership with First Medical Associates, a Leading Primary Care Provider in Maryland

Yahoo

time29 minutes ago

  • Yahoo

Latticework Capital Management Announces Partnership with First Medical Associates, a Leading Primary Care Provider in Maryland

DALLAS, June 24, 2025--(BUSINESS WIRE)--Latticework Capital Management ("Latticework" or "LCM"), a growth oriented private equity firm focused on partnering with entrepreneurially-minded management teams to build leading healthcare companies, today announced a strategic investment in First Medical Associates ("FMA"). Founded by Dr. Rakesh Malik in 2008 and headquartered in Germantown, Maryland, FMA is a trusted, patient-centered primary care provider with eleven clinics across the state. FMA's core mission is to increase access to quality healthcare – providing personalized treatment and care coordination for patients across the health spectrum, from preventative medicine and wellness to sudden illnesses and chronic diseases. "We are thrilled to partner with Dr. Malik and reinforce FMA's vision, empowering FMA providers to continue delivering outstanding care and patient outcomes," said Kyle Bradford, Managing Partner of Latticework. "We are highly impressed with the dedication of the clinicians and staff at the organization, and we look forward to supporting FMA's providers as they continue enriching patient lives through dependable and personalized care to their communities." Latticework has completed more than 150 transactions across a diverse array of healthcare subsectors. The firm employs a "top down" approach to investing, identifying industry themes and trends and focusing on areas of growth and opportunity. "Our mission has always been to deliver compassionate, high-quality care to our local communities. We are excited to partner with Latticework to enhance care for our current communities and to increase access to care across new geographies and specialties," said Dr. Malik, founder of FMA. "We are impressed by Latticework's expertise and track record in scaling multisite healthcare businesses, both through de novos and add on acquisitions, and look forward to employing that playbook for our next stage of growth." "Access to high quality primary care is imperative for a functioning healthcare system, leading to better health outcomes and reducing downstream costs," said Ben McCown, Principal of Latticework. "We are excited to assist Dr. Malik in expanding FMA's reach and services to more patients." Latticework Capital Managing Partner Kyle Bradford, Managing Partner Steve Neumann, Principal Ben McCown, Vice President Travis Hennessey and Associate Ruslan Gabidoulline worked on the transaction. Funds managed by PennantPark Investment Advisers, LLC provided the debt financing to support the acquisition and continued growth of FMA. McGuireWoods LLP served as legal counsel to Latticework, Norton Rose Fulbright LLP served as legal counsel to PennantPark, and Roetzel & Andress LP served as legal counsel to FMA in the transaction. About First Medical Associates:Founded by Dr. Rakesh Malik in 2008 and headquartered in Germantown, Maryland, First Medical Associates is a trusted primary care provider with eleven clinics across the state. FMA's core mission is to increase access to care – providing personalized treatment and care coordination for patients across the health spectrum, from preventative medicine and wellness to sudden illnesses and chronic diseases. First Medical Associates professionals focus on providing superior medical care in a respectful, patient-centered environment. To learn more visit About Latticework Capital Management:Headquartered in Dallas, TX, with an office in Denver, CO, Latticework is a growth oriented private equity firm focused exclusively on making control equity investments in the healthcare industry. LCM has completed more than 150 transactions across a diverse array of healthcare subsectors and currently has more than $650 million in assets under management. LCM leverages its more than 100 combined years of healthcare and investing experience, as well as its network of industry executives, to help companies grow and realize their full long-term value. For more information, please visit View source version on Contacts Jeremy MilnerGregory FCAjmilner@ (401) 862-9422 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Yahoo

time30 minutes ago

  • Yahoo

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW – – Vidofludimus Calcium Continues to Demonstrate Favorable Safety and Tolerability Profile; Long-Term Data Now Available up to 5.5 Years – NEW YORK, June 24, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today reported new long-term open-label extension (OLE) data from its phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS). "It is meaningful to see that patients treated with vidofludimus calcium during the OLE period of our phase 2 EMPhASIS trial in RRMS experienced a low rate of confirmed disability worsening (CDW) events, as measured by the Expanded Disability Status Scale (EDSS). This data, representing approximately 952 treatment years, further underlines our belief that vidofludimus calcium holds great potential to effectively manage the disease, help preserve neurological function, allow patients to maintain independence and improve long-term quality of life," stated Andreas Muehler, M.D., M.B.A., Chief Medical Officer of Immunic. The data at week 144 showed that 92.3% of patients remained free of 12-week CDW, and 92.7% free of 24-week CDW. A total of 29 CDW events were confirmed at 12 weeks following the trigger event through week 144. Of these, 44.8% were associated with relapse-associated worsening (RAW), while only 13.8% were associated with progression independent of relapse activity (PIRA). Additionally, the cumulative data available from the EMPhASIS OLE period, thus far, further reinforces the favorable safety and tolerability profile of vidofludimus calcium, showing low discontinuation rates and low rates of treatment-emergent and serious adverse events. Importantly, no new safety signals have emerged during treatment durations up to 5.5 years. "This new data from the OLE period is very encouraging and continues to corroborate the prior strong results we observed in our phase 2 EMPhASIS trial in RRMS," stated Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. "The ability to maintain remarkably low rates of disability progression is among the most important unmet needs in relapsing MS despite the availability of multiple anti-inflammatory drugs approved for the treatment of MS relapses. By delaying disease progression, MS patients maintain greater independence, face a lower burden in managing their symptoms and experience more favorable long-term outcomes." "Additionally, previously announced data across our multiple sclerosis (MS) program, including from the EMPhASIS trial as well as our recent top-line data from the phase 2 CALLIPER trial in progressive multiple sclerosis, has further highlighted vidofludimus calcium's potential to slow disease progression in MS and substantiated its neuroprotective capabilities through the activation of the Nurr1 target. As a reminder, despite 30-years of commercially available MS treatments, slowing and preventing disease progression still remains a critical unmet need. Based on the data we have generated, to date, we continue to believe that vidofludimus calcium, with its combined neuroprotective, anti-inflammatory and anti-viral effects as well as its established, highly favorable safety and tolerability profile, could represent a unique new oral therapy targeted to the complex pathophysiology of MS." The phase 2 EMPhASIS trial was an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group study, designed to assess the efficacy and safety of vidofludimus calcium in patients with RRMS. The trial randomized 268 RRMS patients and included a 24-week blinded main treatment period testing 10, 30 and 45 mg of vidofludimus calcium and placebo. The trial achieved both primary and key secondary endpoints with high statistical significance and showed a favorable safety and tolerability profile similar to placebo. The trial includes an optional OLE period for up to 9.5 years to evaluate long-term safety and tolerability of vidofludimus calcium. Of the 268 patients that started the double-blind main treatment period, 254 patients continued in the OLE period. Patients were initially given either 30 mg or 45 mg of vidofludimus calcium once-daily, following which all patients received 30 mg of vidofludimus calcium once-daily. At the time of data cutoff on January 14, 2025, 182 patients (71.6% of patients starting OLE) were evaluated up to week 144, which translates into approximately 952 overall treatment years. About Vidofludimus Calcium (IMU-838)Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Vidofludimus calcium is currently being evaluated in phase 3 clinical trials for the treatment of relapsing MS. In a phase 2 clinical trial, it has shown therapeutic activity in relapsing-remitting MS patients, significantly reducing brain lesions and demonstrating encouraging results in reducing confirmed disability worsening. Additionally, vidofludimus calcium has demonstrated clinical benefits in progressive MS patients by showing substantial reductions in confirmed disability worsening and thalamic brain volume in a phase 2 clinical trial. To date, vidofludimus calcium has been exposed to approximately 2,700 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. Vidofludimus calcium is not yet licensed or approved in any country. About Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at or Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, BreuVice President Investor Relations and Communications+49 89 2080 477 US IR ContactRx Communications GroupPaula Schwartz+1 917 633 7790immunic@ US Media ContactKCSA Strategic CommunicationsCaitlin Kasunich+1 212 896 1241ckasunich@ View original content to download multimedia: SOURCE Immunic, Inc. Sign in to access your portfolio

Pager Health(SM) Appoints Nationally Recognized Clinician to Lead Medical Strategy and Innovation
Pager Health(SM) Appoints Nationally Recognized Clinician to Lead Medical Strategy and Innovation

Yahoo

time30 minutes ago

  • Yahoo

Pager Health(SM) Appoints Nationally Recognized Clinician to Lead Medical Strategy and Innovation

NEW YORK, June 24, 2025 /PRNewswire/ -- Pager Health, a connected health company that enables people to engage, navigate and access the right care in the right place at the right time, today announced the appointment of clinician, operator and innovator Dr. Ken Yamaguchi as Chief Medical Officer. Dr. Yamaguchi will help bring clinical leadership, expertise and guidance to Pager Health's product strategy, business development and care operations. "Dr. Yamaguchi brings more than 30 years of leadership at the intersection of clinical care, health system strategy, and medical innovation." said Walter Jin, Chairman and CEO of Pager Health. "He played a pivotal role at Centene, helping scale the company by over $100 billion in revenue while overseeing approximately 1,000 personnel and indirectly guiding several thousand medical and affiliated staff. He now brings his cross-disciplinary background to Pager Health, where he will drive clinical innovation, deepen medical partnerships, and ensure the company's solutions deliver measurable, real-world impact." Dr. Yamaguchi is Professor of Orthopedic Surgery at Northwestern University Feinberg School of Medicine and previously served on Centene's executive team (2015–2022), overseeing medical strategy during a period of rapid growth. Before that, he was the Sam and Marilyn Fox Distinguished Professor at Washington University and team physician for the St. Louis Cardinals. He holds a BA and MS from UCLA and an MBA from Washington University's Olin School of Business. Dr. Yamaguchi has authored over 200 publications, delivered more than 70 visiting professorships at leading institutions including Johns Hopkins, Harvard, Penn, Brown, Dartmouth, Peking University, and Oxford, and is co-founder of Protera Health, a digital MSK provider. He has also served on the executive committees of the American Orthopedic Association and American Shoulder and Elbow Surgeons, as deputy editor for the Journal of Bone and Joint Surgery, and on the board of directors of the American Academy of Orthopedic Surgeons. For more information about Pager Health, please visit About Pager HealthPager Health is a connected health platform company that enables healthcare enterprises to deliver high-engagement, intelligent health experiences across wellness, care navigation, and care management engagement. Through integrated technology, AI, and concierge services, our platform helps patients and members get the right care at the right time in the right place and stay healthy. By reducing system friction and fragmentation, powering engagement, and orchestrating the enterprise, Pager Health drives better outcomes at scale. We partner with leading payers, providers, and employers, representing more than 26 million individuals across the United States and Latin America. Media ContactPager HealthChristopher Galechris@ View original content: SOURCE Pager Health

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store